Oxford Cancer Analytics

About Oxford Cancer Analytics

Oxford Cancer Analytics (OXcan) is a medtech company focused on enabling curative cancer treatment through early detection. Originating from Oxford, their mission is to bring hope to cancer patients and families worldwide by leveraging a multidisciplinary team with expertise in cancer research, clinical medicine, machine learning, and business.

Products & Services

DEcancer ML Platform:A blood-based liquid biopsy platform using advanced proteomics and AI for early cancer detection, with versatile applications.

Specialties

Early Cancer Detection Blood-based Liquid Biopsy Proteomics Artificial Intelligence (AI) Lung Cancer Research

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 11000000 MR: - FA: US$11 million FAN: 11000000	D: 2025-01-09 FD: 2025-01-09	9 investors

Series A Latest

2025-01-09

$11.0M

9 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

P

Peter Jianrui Liu

Chief Executive Officer

LinkedIn (Pro only)

A

Andreas Halner

President & Chief Operating Officer

LinkedIn (Pro only)

D

Daniel Szulc

Chief Product Officer

LinkedIn (Pro only)

H

Heinrich Roder

Senior Vice President, Research & Development

E

Ella Mi

Head of Medical and Regulatory Affairs

N

Nikola Gushterov

Senior Machine Learning Scientist

View 18 more team members with Pro

Unlock Full Team Directory

Recent News